Barinthus Biotherapeutics PLC
BRNS
View Detailed Chart
0.705USD
-0.038-5.06%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
28.78MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-5.06%
5 Days
-3.42%
1 Month
-0.72%
6 Months
-46.18%
Year to Date
+0.70%
1 Year
-29.50%
View Detailed Chart
TradingKey Stock Score of Barinthus Biotherapeutics PLC
Currency: USD Updated: 2026-02-06Key Insights
Barinthus Biotherapeutics PLC's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 142 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 5.50.In the medium term, the stock price is expected to trend down.Despite a weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Barinthus Biotherapeutics PLC's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Barinthus Biotherapeutics PLC Highlights
StrengthsRisks
Barinthus Biotherapeutics plc is a clinical-stage biopharmaceutical company focused on developing immunotherapeutic candidates for treating autoimmune and inflammatory diseases. The Company’s pipeline, built around platform technologies; viral vector-based, consists of ChAdOx and MVA, and synthetic, consisting of SNAP-Tolerance Immunotherapy (SNAP-TI). These platforms help to develop antigen-specific immunotherapeutic candidates designed to optimize the disease fighting capabilities of T cells. It is focused on developing two product candidates that harness its viral vector and synthetic platform technologies. These include VTP-300, a Phase II immunotherapeutic candidate designed as a potential component of a functional cure for chronic hepatitis B virus infection utilizing ChAdOx/MVA, and VTP-1000, its autoimmune candidate designed to utilize the SNAP-TI platform to treat patients with celiac disease. The Company's pipeline also includes VTP-850, VTP-500 and VTP-400.
Growing
The company is in a growing phase, with the latest annual income totaling USD 14.97M.
Overvalued
The company’s latest PE is -0.37, at a high 3-year percentile range.
Held by James Simons
Star Investor James Simons holds 66.30K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.89.
Analyst Rating
Based on
2
analysts
Buy
Current Rating
5.500
Target Price
+640.64%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Barinthus Biotherapeutics PLC News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Barinthus Biotherapeutics PLC Info
Barinthus Biotherapeutics plc is a clinical-stage biopharmaceutical company focused on developing immunotherapeutic candidates for treating autoimmune and inflammatory diseases. The Company’s pipeline, built around platform technologies; viral vector-based, consists of ChAdOx and MVA, and synthetic, consisting of SNAP-Tolerance Immunotherapy (SNAP-TI). These platforms help to develop antigen-specific immunotherapeutic candidates designed to optimize the disease fighting capabilities of T cells. It is focused on developing two product candidates that harness its viral vector and synthetic platform technologies. These include VTP-300, a Phase II immunotherapeutic candidate designed as a potential component of a functional cure for chronic hepatitis B virus infection utilizing ChAdOx/MVA, and VTP-1000, its autoimmune candidate designed to utilize the SNAP-TI platform to treat patients with celiac disease. The Company's pipeline also includes VTP-850, VTP-500 and VTP-400.
Ticker SymbolBRNS
CompanyBarinthus Biotherapeutics PLC
CEOEnright (William J)
Websitehttps://www.barinthusbio.com/
Related Instruments
+3.66%
+3.14%
+0.93%
+2.01%
+1.82%
+1.60%
-0.95%
+4.49%
+2.10%
+9.92%
+2.76%
+4.15%
+1.79%
+4.17%
+0.72%
+1.10%
+2.46%
0.00%
+0.51%
+0.54%Popular Symbols
278.120
+2.210 (+0.80%)
185.410
+13.530 (+7.87%)
68595.320
-1374.810 (-1.97%)
282.580
+22.390 (+8.61%)
2038.240
-13.490 (-0.66%)
411.110
+13.900 (+3.50%)
4952.980
+142.360 (+2.96%)
63.303
+0.206 (+0.33%)
1.182
+0.004 (+0.35%)
157.098
+0.057 (+0.04%)
